Integra LifeSciences Holdings Corporation — Q1 2016 Form 10-Q Summary
Business context and reporting period
Integra is a global medical technology company focused on neurosurgery, surgical instruments, extremity orthopedics, wound repair, regenerative technologies, and related products. This report covers the three months ended March 31, 2016, with comparisons to the three months ended March 31, 2015. Results exclude SeaSpine, which was distributed to shareholders on July 1, 2015 and is presented as discontinued operations in the prior-year period.
Key financial metrics
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Revenue | $236.8 million | $202.5 million | 17% |
| Gross profit | $152.0 million | $127.3 million | 19% |
| Gross margin | 64.2% | 62.9% | +130 bps |
| Operating income | $22.1 million | $21.2 million | 4% |
| Operating margin | 9.3% | 10.5% | Down |
| Income from continuing operations | $11.6 million | $11.7 million | Flat |
| Net income | $11.6 million | $8.4 million | 39% |
| Diluted EPS | $0.31 | $0.25 | 24% |
| Operating cash flow | $19.2 million | $31.6 million | Down 39% |
Continuing-operations diluted EPS was $0.31 versus $0.35 in the prior-year period. The higher consolidated prior-year net income comparison reflects a $3.3 million after-tax loss from SeaSpine discontinued operations in Q1 2015. The 2016 effective tax rate was 22.4%, versus 34.1% in Q1 2015; management expects approximately 24% for full-year 2016.
Revenue, segments, cash flow, debt and liquidity
- Specialty Surgical Solutions revenue was $151.2 million, up 8%, led by dural repair and Precision Tools and Instruments, partially offset by lower neuro critical care sales.
- Orthopedics and Tissue Technologies revenue was $85.6 million, up 37%. TEI, Salto and Futura contributed approximately $17.4 million of acquired revenue.
- U.S. revenue was $181.2 million, or 77% of total revenue. International revenue was $55.5 million, up 11%; foreign exchange reduced sales by approximately $1.1 million.
- Operating cash flow from continuing operations was $19.2 million. Working capital consumed approximately $15.0 million, including $18.4 million from accounts receivable and $8.1 million from inventory.
- Capital expenditures were $10.9 million. Management expects approximately $40.0 million of 2016 capital expenditures, primarily for facilities, automation, ERP implementation, and orthopedic instrument kits.
- Cash and cash equivalents were $77.1 million at March 31, 2016, including approximately $38.1 million held by non-U.S. subsidiaries. Working capital was $337.9 million.
- Total borrowings included $509.4 million under the senior credit facility and $220.6 million of convertible securities carrying value. Approximately $585.0 million remained available under the senior credit facility, and the company was in compliance with its covenants.
- The $227.1 million principal amount of 1.625% convertible notes matures in December 2016. Management may refinance, extend, or use available credit capacity to settle the obligation.
Material changes versus the prior comparable period
- Revenue growth primarily reflected the full-period contribution from the 2015 TEI acquisition and the Tornier toe and ankle products, as well as organic growth in regenerative products and dural repair.
- Gross margin improved due to product mix and manufacturing utilization, partly offset by start-up costs at the new collagen manufacturing center.
- Operating expenses increased 22% to $129.9 million. Selling, general and administrative expense rose primarily from increased sales-force headcount and commissions; research and development spending also increased.
- Operating margin declined despite higher gross margin because commercial investments, research and development, acquisition-related costs, and higher amortization increased faster than revenue.
- Interest expense increased to $6.4 million from $5.5 million, primarily because of higher senior credit facility borrowings and $2.1 million of non-cash convertible-debt interest.
- Comprehensive income was $22.9 million versus a $15.7 million comprehensive loss, primarily because foreign currency translation improved by $35.6 million year over year.
Guidance, outlook, risks and unusual items
- Management expects 2016 consolidated gross margin of approximately 64.0%, research and development expense of 5.5% to 6.0% of revenue, selling, general and administrative expense of 45% to 46% of revenue, and an effective tax rate of approximately 24%.
- The FDA approved the company’s PMA supplement for diabetic foot ulcers in January 2016; management anticipated commercializing Omnigraft in June 2016.
- Reported special charges totaled $13.8 million, including ERP implementation, structural optimization, severance, acquisition-related charges, and non-cash convertible-debt interest. Management expects ERP-related capital and integration expense to decline, but some special charges may recur.
- TEI remains subject to an FDA warning letter concerning promotion of SurgiMend for breast surgery applications. No remediation expenses were incurred in the quarter; the FDA may require additional corrective actions.
- Approximately 50 active product-liability cases were pending against TEI. Insurance, Boston Scientific indemnification, and merger-agreement protections provide some coverage, but the ultimate exposure is uncertain.
- Integra is exposed to foreign-currency and variable-rate debt risk. A one-percentage-point change in interest rates would affect annualized debt interest expense by approximately $5.1 million. No interest-rate hedges were outstanding at quarter-end.
- The company had $22.0 million of contingent consideration liabilities and $0.8 million of uncertain tax benefits excluded from the contractual-obligations table because timing or amounts were not fixed.
Most important facts for investors to verify
- Whether acquired-product growth, particularly from TEI, remains sustainable and translates into operating leverage.
- The timing and funding plan for the $227.1 million convertible-note maturity in December 2016.
- Progress and costs associated with the ERP rollout and collagen manufacturing center.
- Resolution of the TEI FDA warning letter and product-liability litigation, including the availability of insurance and indemnification.
- Whether working-capital investment, especially receivables and inventory, normalizes and permits operating cash flow to improve.
- Execution of the Omnigraft launch and the effect of new regenerative, extremity, and dural-repair products on margins and growth.